We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
Read MoreHide Full Article
Shares of Vanda Pharmaceuticals Inc. (VNDA - Free Report) were up 4.5% on May 15 after the company announced positive data from a second phase III study, which evaluated its neurokinin-1 receptor antagonist, tradipitant for preventing vomiting induced by motion sickness.
Data from this second phase III study (Motion Serifos), which was conducted on boats in the coastal waters of the United States, confirmed the earlier results reported from two efficacy studies in which tradipitant was effective in the prevention of vomiting associated with motion.
The double-blind, placebo-controlled study evaluated tradipitant (170 mg and 85 mg) or placebo in participants having a prior history of motion sickness who were on boat trips under different sea conditions.
The primary endpoint of the abovementioned study was to check the effect of tradipitant (170 mg) on vomiting, while secondary endpoints included the effect of tradipitant (85 mg) on vomiting and the effect of tradipitant in preventing severe nausea and vomiting.
Both doses of tradipitant were found to be superior compared with placebo in preventing vomiting as 10.4% and 18.3% of participants who were on tradipitant 170 mg and 85 mg, respectively, had vomiting versus 37.7% of participants who received placebo.
Also, treatment with tradipitant (170 mg) reduced the risk of vomiting by more than 70%, while treatment with tradipitant (85 mg) reduced the risk of vomiting by more than 50% in the given patient population.
Vanda plans to submit a new drug application (NDA) for tradipitant to the FDA for the treatment of motion sickness in the fourth quarter of 2024.
Shares of VNDA have rallied 27% so far this year against the industry’s decline of 4.3%.
Image Source: Zacks Investment Research
Per the company, around 30% of the population in the United States suffers from motion sickness under ordinary travel conditions, including sea, air and land. Also, the FDA has not approved any medicine for treating motion sickness in over 40 years.
Hence, the successful development and potential approval of tradipitant for motion sickness would help to address an expanded patient population in the country.
Tradipitant is currently under review in the United States for the treatment of symptoms of gastroparesis. A decision from the FDA is expected on Sep 18, 2024. If approved, this would be the first indication for tradipitant.
Zacks Rank & Stocks to Consider
Vanda currently has a Zacks Rank #3 (Hold).
Some top-ranked stocks in the healthcare sector are Ligand Pharmaceuticals Incorporated (LGND - Free Report) , Entera Bio Ltd. (ENTX - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . While Ligand sports a Zacks Rank #1 (Strong Buy), Entera Bio and ANI Pharmaceuticals currently carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Ligand’s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, shares of LGND have gained 20.1%.
Earnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 56.02%.
In the past 60 days, estimates for Entera Bio’s 2024 loss per share have narrowed from 75 cents to 25 cents. Year to date, shares of ENTX have surged 336.7%.
ENTX’s earnings beat estimates in three of the trailing four quarters and missed the same once, the average surprise being 6.50%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.43 to $4.44. Year to date, shares of ANIP have jumped 17.6%.
Earnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 53.90%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
Shares of Vanda Pharmaceuticals Inc. (VNDA - Free Report) were up 4.5% on May 15 after the company announced positive data from a second phase III study, which evaluated its neurokinin-1 receptor antagonist, tradipitant for preventing vomiting induced by motion sickness.
Data from this second phase III study (Motion Serifos), which was conducted on boats in the coastal waters of the United States, confirmed the earlier results reported from two efficacy studies in which tradipitant was effective in the prevention of vomiting associated with motion.
The double-blind, placebo-controlled study evaluated tradipitant (170 mg and 85 mg) or placebo in participants having a prior history of motion sickness who were on boat trips under different sea conditions.
The primary endpoint of the abovementioned study was to check the effect of tradipitant (170 mg) on vomiting, while secondary endpoints included the effect of tradipitant (85 mg) on vomiting and the effect of tradipitant in preventing severe nausea and vomiting.
Both doses of tradipitant were found to be superior compared with placebo in preventing vomiting as 10.4% and 18.3% of participants who were on tradipitant 170 mg and 85 mg, respectively, had vomiting versus 37.7% of participants who received placebo.
Also, treatment with tradipitant (170 mg) reduced the risk of vomiting by more than 70%, while treatment with tradipitant (85 mg) reduced the risk of vomiting by more than 50% in the given patient population.
Vanda plans to submit a new drug application (NDA) for tradipitant to the FDA for the treatment of motion sickness in the fourth quarter of 2024.
Shares of VNDA have rallied 27% so far this year against the industry’s decline of 4.3%.
Image Source: Zacks Investment Research
Per the company, around 30% of the population in the United States suffers from motion sickness under ordinary travel conditions, including sea, air and land. Also, the FDA has not approved any medicine for treating motion sickness in over 40 years.
Hence, the successful development and potential approval of tradipitant for motion sickness would help to address an expanded patient population in the country.
Tradipitant is currently under review in the United States for the treatment of symptoms of gastroparesis. A decision from the FDA is expected on Sep 18, 2024. If approved, this would be the first indication for tradipitant.
Zacks Rank & Stocks to Consider
Vanda currently has a Zacks Rank #3 (Hold).
Some top-ranked stocks in the healthcare sector are Ligand Pharmaceuticals Incorporated (LGND - Free Report) , Entera Bio Ltd. (ENTX - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . While Ligand sports a Zacks Rank #1 (Strong Buy), Entera Bio and ANI Pharmaceuticals currently carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Ligand’s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, shares of LGND have gained 20.1%.
Earnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 56.02%.
In the past 60 days, estimates for Entera Bio’s 2024 loss per share have narrowed from 75 cents to 25 cents. Year to date, shares of ENTX have surged 336.7%.
ENTX’s earnings beat estimates in three of the trailing four quarters and missed the same once, the average surprise being 6.50%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.43 to $4.44. Year to date, shares of ANIP have jumped 17.6%.
Earnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 53.90%.